1. Agid, Y., Barroche, G., Bonnet, A. M., Javoy-Agid, F., Kato, G., Lhermitte, F., Pollak, P., Signoret, J. L.: Dopamine receptor stimulating agonists in the treatment of Parkinson's disease. Biomedicine30, 67?71 (1979).
2. Ahlenius, S.: An analysis of behavioral effects produced by drug-induced changes of dopaminergic neurotransmission in the brain. Scand. J. Psychol.20, 59?64 (1979).
3. Ahlenius, S., Archer, T., Tandberg, B., Hillegaart, V.: Effects of (-)-3-(3-hydoxy-phenyl)-N-n-propylpiperidine (3-PPP), alone and in combination with haloperidol (HPD), on conditioned avoidance behavior, catalepsy and treadmill performance in the rat. Progr. Neuro-Psychopharmacol. Biol. Psychiat. (suppl.),65 (abstr. no. 5) (1983).
4. Ahlenius, S., Archer, T., Tandberg, B., Hillegaart, V.: Effects of (-)-3-PPP on acquisition and retention of a conditioned avoidance response in the rat. Psychopharmacol.84, 441?445 (1984 a).
5. Ahlenius, S., Hillegaart, V., Magnusson, O., Lundström, J.: Behavioral and biochemical effects of subchronic treatment with (-)-3-(3-hydroxyphenyl)N-n-propylpiperidine in the rat: dopamine receptor sensitivity and tolerance. J. Neural Transm.60, 103?113 (1984 b).